Seeking Alpha
 

Acorda Therapeutics, Inc. (ACOR)

- NASDAQ
  • Sep. 24, 2014, 12:46 PM
    | 1 Comment
  • Sep. 24, 2014, 9:20 AM
    | Comment!
  • Sep. 24, 2014, 8:51 AM
    • Acorda Therapeutics (NASDAQ:ACOR) is up 10% premarket on robust volume in response to its acquisition of Civitas Therapeutics.
    | Comment!
  • Jun. 17, 2014, 12:50 PM
    | Comment!
  • Mar. 6, 2014, 5:40 PM
    | Comment!
  • Feb. 28, 2014, 5:40 PM
    | Comment!
  • Jan. 13, 2014, 11:12 AM
    • Shares of Acorda Therapeutics (ACOR +4.2%) are higher in morning trading after the company provided preliminary financial results in connection with the JPMorgan Healthcare Conference.
    • Q4 and FY Ampyra net sales: $84M and $302M, respectively.
    • 2014 Ampyra net sales guidance: $328-335M.
    • 2014 opex guidance: R&D, $60-70M; SG&A, $180-190M.
    • 2014 Zanaflex guidance and ex-U.S. Fampyra revenue: $25M
    • PR
    | Comment!
  • Oct. 14, 2013, 3:40 PM
    • Acorda Therapeutics (ACOR -8.4%) falls despite reporting what the company calls "positive" results for a dalfampridine-ER proof-of-concept study in patients with post-stroke deficits.
    • The treatment was "was well-tolerated and improved walking, as measured by the Timed 25-Foot Walk test." (PR)
    • RBC's Michael Yee says that while the post-stroke data "is interesting," it is "not as compelling versus the MS indication."
    • Speaking of the MS indication, Yee says "scripts look a bit mediocre tracking a tad shy of Q3 consensus, and overall new scripts are down too."
    • Nevertheless, RBC says "expectations are pretty low and ... the stock is pretty cheap at $1.1B EV or ~3x sales plus all potential upside from label expansion or pipeline."
    | Comment!
  • Jul. 5, 2013, 5:30 PM
    After-hours top gainers, as of 5:15 p.m.: ELP +3%. CIG +2%. NBG +2%. HSOL +2%. EZPW +1%.
    After-hours top losers: JASO -6%. SCHL -5%. CIK -4%. NPBC -4%. ACOR -4%.
    | Comment!
  • May. 20, 2013, 12:31 PM
    Acorda Therapeutics (ACOR -1%) is issued a patent for Amprya entitled "Methods of Using Sustained Release Aminopyridine Compositions." This patent covers a range of dosage strengths, and is separate from 2 method of use patents issued in 2011 and 2013 that are set to expire in 2027 and 2026, respectively. The drug is approved in the United States as a treatment to improve walking in patients with multiple sclerosis.
    | Comment!
  • Apr. 16, 2013, 2:17 PM
    Acorda Therapeutics (ACOR +11.2%) rises for a second day after AMPYRA shows promise for post-stroke deficit patients. Heard on the conference call: 1) "What got us here [is] an adherence to analysis in science [and] we're not going to deviate from that" just to get into a Phase III trial. 2) An 18-20% improvement in the timed 25-foot walk speed "correlates very well with various measures of clinically meaningful improvement," but the comparison between the current study and the MS study "is not apples-to-apples."
    | Comment!
  • Apr. 16, 2013, 12:59 PM
    Midday top 10 gainers: UNXL +16%. CNIT +15%. ANEN +15%. CHCI +14%. SYNM +13%. PNFP +12%. EVC +12%. ENPH +11%. NCQ +11%. ACOR +11%.
    Midday top 10 losers: JAXB -33%. KEYN -15%. SRPT -12%. CPGI -10%. GENE -10%. TRIT -9%. CCXI -9%. MAGS -9%. ADAT -8%. GAI -8%.
    | Comment!
  • Apr. 15, 2013, 12:50 PM
    Midday top 10 gainers: MKTAY +143%. CNIT +21%. GENE +21%. THRX +18%. MCOX +17%. SGRP +14%. S +13%. STXS +10%. ACOR +9%. LIFE +8%.
    Midday top 10 losers: UNTK -48%. GSS -19%. ASM -18%. DSCO -17%. HXM -16%. XPL -16%. NGD -16%. TGD -15%. BAA -14%. PZG -14%.
    | Comment!
  • Apr. 15, 2013, 8:24 AM
    Acorda Therapeutics (ACOR) says a proof-of-concept trial shows AMPYRA, the company's FDA approved walking treatment for multiple sclerosis, also improves walking in patients with post-stroke deficits. ACOR says once it has completed its analysis it will consult with the FDA on developing the drug for use by stroke survivors. Shares +8.6% premarket. 
    | Comment!
  • Feb. 13, 2013, 11:20 AM
    Acorda Therapeutics (ACOR +1.9%) hits new 52-week highs after it reported better-than-expected results for Q4. Revenue for the quarter came in at $81.5 million, beating the $78.90 million consensus. Additonally, the company says it plans to submit an NDA to the FDA for a diazepam nasal spray in 2013.
    | Comment!
  • Oct. 31, 2012, 1:49 PM
    Acorda Therapeutics (ACOR +7.4%) trades up after its Q3 earnings beat estimates this morning. Sales of lead product Ampyra came in at $69M for the period, up 5% Y/Y, and above the Consensus expectations of $68M. The company also said that it is reaffirming its 2012 Ampyra net sales guidance of $255M - $275M.
    | Comment!
Visit Seeking Alpha's
ACOR vs. ETF Alternatives
Company Description
Acorda Therapeutics, Inc. is a biopharmaceutical company. It is engaged in the identification, development & commercialization of novel therapies for the treatment of multiple sclerosis, spinal cord injury & other disorders of the central nervous system.
Sector: Healthcare
Industry: Biotechnology
Country: United States